2 Stocks Down 30% and 27% to Buy and Hold
No pair of companies dominated the COVID-19 vaccine market quite like (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as governments rushed to buy millions of doses of their respective vaccines. However, this tailwind came to a screeching halt as the pandemic receded, and the market reacted accordingly.
Pfizer and Moderna have been trailing broader equities for the better part of two years. Still, there remain good reasons to invest in these stocks, at least for investors focused on the long term. Let's find out more.
Investors became disenchanted with Pfizer because, beyond its declining coronavirus-related sales, the rest of the company's lineup didn't seem capable of driving solid top-line growth. Pfizer shares have fallen 30% over the past year.
Source Fool.com
Pfizer Inc. Aktie
Überwältigendes Buy-Interesse bei Pfizer Inc., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Pfizer Inc. mit einem Kursziel von 41 € im Vergleich zum aktuellen Kurs von 26.41 € zu erwarten.
